KALA BIO (KALA) investor relations material

Company overview and business model

• Transitioning from biopharmaceutical R&D to developing an on-premises AI infrastructure platform for the biotechnology industry, leveraging proprietary clinical datasets and IP from discontinued ophthalmology programs.

• Entered an exclusive license for the Researgency AI research platform to serve biotech and pharma clients, aiming to enable secure, agentic AI research without loss of data control.

• Strategy includes monetizing legacy biologics assets and deploying the AI platform as a platform-as-a-service, targeting mid-size biotech, CROs, and pharma companies.

Financial performance and metrics

• No ongoing clinical trials; focus is on asset monetization and AI platform development.

• Common stock last traded at $0.1151 per share on May 6, 2026, prior to a 1-for-50 reverse stock split.

Use of proceeds and capital allocation

• Net proceeds from any securities sales will be used for general corporate purposes, including product development, manufacturing, sales, marketing, and working capital.

• Management retains broad discretion over allocation of proceeds; may invest in short-term, investment-grade securities or reduce short-term debt.